Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq:IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Related news for (IMRX)
- MoBot’s Stock Market Highlights – 09/25/25 08:00 AM
- Spider Silk, Splicing & Strategic Capital: Biotech and Innovation Dominate the Morning Tape
- Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/25/25 07:00 AM
- 24/7 Market News Snapshot 25 September, 2025 – Immuneering Corporation Class A Common Stock (NASDAQ:IMRX)